Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers

Jeil Pharmaceutical logo

Jeil Pharmaceutical

Status and phase

Completed
Phase 1

Conditions

Diabetes
Hyperlipidemia

Treatments

Drug: JLP-1310, Fasted followed by fed
Drug: JLP-1310, Fed followed by fasted

Study type

Interventional

Funder types

Industry

Identifiers

NCT02449187
JLP-1310-102-FE

Details and patient eligibility

About

A randomized, open-label, single dose, crossover study to investigate the effect of food on the pharmacokinetics of JLP-1310 in healthy male volunteers.

Full description

A randomized, open-label, single dose, crossover clinical trial.

Enrollment

16 patients

Sex

Male

Ages

19+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male volunteer, age is over 19 years
  • Body weight is over 55kg, The result of Body Mass Index(BMI) is not less than 17.5 kg/m2 , no more than 30.5 kg/m2
  • Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial
  • Subject who has the ability and willingness to participate the whole period of trial

Exclusion criteria

  • Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system.
  • Subjects who are allergic to investigational drug.
  • Subjects who have a medical history which can affect the clinical trial.
  • Hypertension(Systolic BP ≥ 140mmHG or Diastolic BP ≥ 90mmHg), Liver enzyme (AST, ALT) level exceeds the maximum normal range more than one and a half times.
  • History of drug abuse or positive drug screening.
  • Participation in other drug studies within 3 months prior to the drug administration.
  • Whole blood donation within 60 days, blood component donation within 30 days or who got transfusion within 30days.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

16 participants in 2 patient groups

JLP-1310, Fasted followed by fed
Experimental group
Description:
JLP-1310 dosing in the fasted state followed by fed dosing Interventions: Drug: JLP-1310
Treatment:
Drug: JLP-1310, Fasted followed by fed
JLP-1310, Fed followed by fasted
Experimental group
Description:
JLP-1310 dosing in the fasted state followed by fed dosing Interventions: Drug: JLP-1310
Treatment:
Drug: JLP-1310, Fed followed by fasted

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems